Use of psychotropic drugs and analgesics among users of antiobesity drugs - A population based study

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 3, 2010, Pages 273-279

  Amundsen, Merethe Omdal ^a   Engdahl, Bo ^b   Berg, Christian ^b   Nordeng, Hedvig ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Analgesics; Concomitant drug use; Orlistat; Psychotropic drugs; Rimonabant; Sibutramine

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RIMONABANT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CONTROLLED STUDY; DATA EXTRACTION; DEPRESSION; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS; ANTI-OBESITY AGENTS; CHILD; CYCLOBUTANES; DATABASES, FACTUAL; DRUG INTERACTIONS; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PIPERIDINES; PSYCHOTROPIC DRUGS; PYRAZOLES; SEX FACTORS; YOUNG ADULT;

EID: 77649196737     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1896     Document Type: Article

References (33)

1. WHO. 2006; Obesity and overweight. What are overweight and obesity? http://www.who.int/mediacentre/factsheets/fs311/en/index. html (accessed 30 January 2008).
2. de Wit LM, van Straten A, van Herten M, Penninx BW, Cuijpers P. Depression and body mass index, a u-shaped association. BMC Public Health 2009; 9: 14.
3. Zhao G, Ford ES, Dhingra S, Li C, Strine TW,Mokdad AH. Depression and anxiety among US adults: associations with body mass index. Int J Obes (Lond) 2009; 33: 257-266.
4. Finzi-Dottan R, Zubery E. The role of depression and anxiety in impulsive and obsessive-compulsive behaviors among anorexic and bulimic patients. Eat Disord 2009; 17: 162-182.
5. Barry D, Pietrzak RH, Petry NM. Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Ann Epidemiol 2008; 18: 458-466.
6. McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB. Chronic pain and obesity in elderly people: results from the einstein aging study. JAm Geriatr Soc 2009; 57: 115-119.
7. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008; 9: 132.
8. Rogers MW, Wilder FV. The association of BMI and knee pain among persons with radiographic knee osteoarthritis: a cross-sectional study. BMC Musculoskelet Disord 2008; 9: 163.
9. Friedman MA, Brownell KD. Psychological correlates of obesity: moving to the next research generation. Psychol Bull 1995; 117: 3-320.
10. Fitzgibbon ML, Stolley MR, Kirschenbaum DS. Obese people who seek treatment have different characteristics than those who do not seek treatment. Health Psychol 1993; 12: 342-345.
11. Wadden TA, Butryn ML, Sarwer DB, et al. Comparison of psychosocial status in treatment-seeking women with class III vs. class I-II obesity. Surg Obes Relat Dis 2006; 2: 138-145.
12. Counterweight Project Team. The impact of obesity on drug prescribing in primary care. Br J Gen Pract 2005; 55: 743-749.
13. van Dijk L, Otters HB, Schuit AJ. Moderately overweight and obese patients in general practice: a population based survey. BMC Fam Pract 2006; 7: 43.
14. The Norwegian Medicines Agency. SPC - Orlistat. http://www. legemiddelverket.no/custom/templates/gzInterIFrame-61197.aspx (accessed 05 February 2008).
15. The Norwegian Medicines Agency. SPC - Sibutramine. http://www. legemiddelverket.no/custom/templates/gzInterIFrame-61197.aspx (accessed 05 February 2008).
16. Rucker D, Padwal R, Li SK, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J 2007; 335: 1194-1199.
17. The Norwegian Medicines Agency. SPC - Rimonabant. http://www. legemiddelverket.no/custom/templates/gzInterIFrame-61197.aspx (accessed 05 February 2008).
18. EMEA. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia 2008. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/acomplia/53777708en.pdf (accessed 24 October 2008).
19. EMEA. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant), 2008. http://www.emea.europa. eu/humandocs/PDFs/EPAR/acomplia/53715308en.pdf (accessed 16 February 2009).
20. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. Quart J Med 2007; 100: 395-404.
21. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24: 59-73.
22. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007; 63: 205-209.
23. Pokras SM, Klingman D, Tierce JC. Factors associated with prescription of obesity medications in the US. Pharmacoepidemiol Drug Saf 2008; 17 (Suppl 1): S143 (abstract 326).
24. Pokras SM, Klingman D, Annunziata K, Chapnick J, Tierce J. Utilization and patient experience with obesity prescriptions in the US. Pharmacoepidemiol Drug Saf 2008; 17 (Suppl 1): S142 (abstract 324).
25. Rønning M, Berg CL, Furu K, Litleskare I, Sakshaug S, Strøm H. Rapport 2008: The Norwegian Prescription Database 2004-2007. Norwegian Inst Public Health: 2008.
26. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. WHO: Oslo, 2007.
27. Tobi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LT. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 2007; 16: 405-411.
28. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478-484.
29. Ulset E, Undheim R, Malterud K. Has the obesity epidemic reached Norway? Tidsskr Nor Lægeforen 2007; 127: 34-37. Article inNorwegian.
30. Ministry of Health and Care Services. Women's health in Norway. Chapter 1.9: Gender perspectives on health services and -consumptions. NOU, 1999: 13. Text in Norwegian.
31. Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Pract 2008; 58(553): 548-554.
32. Rønning M, Sakshaug S, Strøm H, Berg CL, Litleskare I, Devold H, Blix HS, Granum T. Drug consumption in Norway 2003-2007. Norwegian Institute of Public Health, Oslo, Norway: 2008.
33. Linné Y, Rooth P, Rössner S. Success rate of Orlistat in primary-care practice is limited by failure to follow prescribing recommendations: the referral letter content vs. clinical reality. Int J Obes Relat Metab Disord 2003; 27: 1434-1435.